Cabozantinib, an orally bioavailable inhibitor of tyrosine kinases including tyrosine-protein kinase Met (MET), Axl receptor tyrosine kinase (AXL), Ret receptor tyrosine kinase (RET), FMS-like receptor tyrosine kinase-3 (FLT3), and VEGF receptors, has also been approved for HCC patients who have been previously treated with sorafenib. The gene discussed is FLT3; the disease is hepatocellular carcinoma.